MDedge

www.mdedge.com is a news site that provides the latest medical news, peer-reviewed clinical content, conference coverage, and free CME/CE quizzes to its users. The site also features research summaries and interviews with experts in various fields of medicine. The primary topics covered by the site include perinatal mental health care accessibility, lung cancer screening, RSV infections and cardiovascular events, air pollution data in public health, migraine disability rates, and more.

70%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on its reporting.

Bias

0%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

75%

Examples:

  • Barriers to accessing mental healthcare prevent women from receiving treatment and getting well.
  • Women face difficulties accessing perinatal mental health resources, despite the availability of treatments in reproductive psychiatry.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • New Hope in Treating Postpartum Depression: The Role of Zuranolone (Zurzuvae)

    New Hope in Treating Postpartum Depression: The Role of Zuranolone (Zurzuvae)

    Broke On: Tuesday, 21 May 2024 Zuranolone, the first pill designed to treat postpartum depression (PPD), offers hope for new mothers suffering from this common yet often overlooked mental health condition. With promising results in clinical trials and FDA approval in August 2023, this neurosteroid medication can alleviate symptoms such as anxiety, difficulty sleeping, and low energy within three days. However, despite increased awareness and advancements in treatment options like Zuranolone, many women still face barriers when seeking help for PPD. Healthcare providers play a crucial role in identifying at-risk women and ensuring they receive appropriate care to overcome these barriers.